Skip to main content

Advertisement

SpringerLink
Log in

Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report 12-year follow-up experience with topical mitomycin chemotherapy for diffuse and multifocal primary acquired melanosis (PAM) with atypia and conjunctival melanoma.

Methods

Interventional case series of 16 patients. Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma. Primary treatments consisted of mitomycin 0.04% qid for 28 days (two 14-day cycles) and for 7 consecutive days as adjuvant therapy. Patients were followed for both local recurrence and metastatic disease.

Results

Sixteen patients were followed for a mean 81 months (range 13–144 months) after treatment. All tumors responded to chemotherapy. Recurrence was noted in eight (three adjuvant and five primary treatment patients). Three underwent orbital exenteration. The remaining five were treated conservatively. The mean time to recurrence was 36.9 months. The short-term mitomycin-related complications included transient keratoconjunctivitis (n=14), severe keratoconjunctivitis (n=1) and one corneal abrasion with scar formation. The long-term complications included pannus (n=2) and corneal haze (n=1). Visual acuity was maintained within two lines in 14 patients (including measurements just prior to exenteration). Three patients died, one of metastatic conjunctival melanoma.

Conclusions

Conjunctival melanoma and PAM responded to mitomycin 0.04% topical chemotherapy; subepithelial nests appeared resistant to treatment. Treatment-related complications were acceptable. In this series, as primary and adjuvant therapy, topical mitomycin yielded an overall recurrence rate of 50%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Billing K, Karagiannis A, Selva D (2003) Punctal-canalicular stenosis associated with mitomycin C for corneal epithelial dysplasia. Am J Ophthalmol 136:746–747

    Article  PubMed  Google Scholar 

  2. Crawford JB (1980) Conjunctival melanomas: prognostic factors: a review and analysis of a series. Trans Am Ophthalmol Soc 78:467–502

    PubMed  CAS  Google Scholar 

  3. Demirci H, McCormick SA, Finger PT (2000) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia. Clinical experience with histopathologic observations. Arch Ophthalmol 118:885–891

    PubMed  CAS  Google Scholar 

  4. De Potter P, Shields CL, Shields JA, Menduke H (1993) Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol 77:624–630

    Article  PubMed  Google Scholar 

  5. Dogru M, Ertuck H, Shimazaki J, Tsubota K, Gul M (2003) Tear function and ocular surface changes with topical mitomycin treatment for primary corneal intraepithelial neoplasia. Cornea 22:627–639

    Article  PubMed  Google Scholar 

  6. Donnenfeld ED, Perry HD, Fromer S, Doshi S, Solomon R, Biser S (2003) Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology 110:1012–1026

    Google Scholar 

  7. Donnenfeld ED, Perry HD, Wallerstein A, Caronia RM, Kanellopoulos AJ, Sforza PD, D’Aversa G (1999) Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology 106:72–78

    CAS  Google Scholar 

  8. Finger PT, Milner MS, McCormick SA (1993) Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 77:751–753

    Article  PubMed  CAS  Google Scholar 

  9. Finger PT, Czechonska G, Liarikos S (1998) Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 82:476–479

    Article  PubMed  CAS  Google Scholar 

  10. Fourman S (1995) Scleritis after glaucoma filtering surgery with mitomycin C. Ophthalmology 102:1569–1571

    CAS  Google Scholar 

  11. Frucht-Pery J, Pe’er J (1996) Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthalmol. 114:1261–1264

    PubMed  CAS  Google Scholar 

  12. Frucht-Pery J, Sugar J, Baum J et al (1997) Mitomycin C treatment for conjunctival–corneal intraepithelial neoplasia: a multicenter experience. Ophthalmol 104:2085–2093

    CAS  Google Scholar 

  13. Gupta S, Basti S (1992) Corneoscleral, ciliary body and vitreoretinal toxicity after excessive installation of mitomycin C. Am J Ophthalmol 104:503–504

    Google Scholar 

  14. Jakobiec FA, Brownstein S, Albert W, Schwartz F, Anderson R (1982) The role of cryotherapy in the management of conjunctival melanoma. Ophthalmology 108:502–512

    Google Scholar 

  15. Jakobiec FA, Rini JD, Fraunfelder FT, Brownstein S (1988) Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Ophthalmology 95:1058–1070

    PubMed  CAS  Google Scholar 

  16. Jakobiec FA, Folberg R, Iwanoto T (1989) Clinicopathologic characteristics for premalignant or malignant lesions of conjunctiva. Ophthalmology 96:147–166

    PubMed  CAS  Google Scholar 

  17. Liesegang TJ, Campbell RJ (1980) Mayo Clinic experience with conjunctival melanomas. Arch Ophthalmol 98:1385–1389

    PubMed  CAS  Google Scholar 

  18. Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P (1990) Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol 74:615–619

    Article  PubMed  CAS  Google Scholar 

  19. Murphy WM, Soloway MS, Crabtree WN (1981) The morphological effects of mitomycin C in mammalian urinary bladder. Cancer 47:2567–2574

    Article  PubMed  CAS  Google Scholar 

  20. Norregaard JC, Grener N, Jensen OA, Prause JU (1996) Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 234:569–572

    Article  CAS  Google Scholar 

  21. Palmer SS (1991) Mitomycin as adjuvant chemotherapy with trabeculectomy. Ophthalmology 98:317–321

    PubMed  CAS  Google Scholar 

  22. Papandroudis AA, Dimitrakos SA, Stangos NT (2002) Mitomycin C therapy for conjunctival–corneal intraepithelial neoplasia. Cornea 21:715–717

    Article  PubMed  Google Scholar 

  23. Paridaens ADA, McCartney ACE, Minnassian DC, Hungerford JL (1994) Orbital exenteration in 95 case of primary conjunctival malignant melanoma. Br J Ophthalmol 78:520–528

    Article  PubMed  CAS  Google Scholar 

  24. Paridaens ADA, Minassian DC, McCartney ACE, Hungerford JL (1994) Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathologic study of 256 cases. Br J Ophthalmol 78:252–259

    Article  PubMed  CAS  Google Scholar 

  25. Rodriguez-Ares T, Tourino R, Rojas VD, et al (2003) Topical mitomycin C in the treatment of pigmented conjunctival lesions. Cornea 22:114–117

    Article  PubMed  Google Scholar 

  26. Rubinfield RS, Pfister RR, Stein RM et al (1992) Serious complications of topical mitomycin C after pterygium surgery. Ophthalmology 99:1647–1654

    PubMed  Google Scholar 

  27. Sacu S, Segur-Eltz N, Horvat R, Lukas JR, Zehetmayer M (2003) Intumescent cataract after topical mitomycin C for conjunctival malignant melanoma. Am J Ophthalmol 136:375–377

    Article  PubMed  Google Scholar 

  28. Salamao DR, Mathers WD, Sutphin JE, Cuevas K, Folberg R (1999) Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology 106:1756–1761

    Article  PubMed  Google Scholar 

  29. Schelonka LP, Siegel D, Wilson MW et al (2000) Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and donor eyes. Inv Ophthalmol Vis Sci 4:1617–1622

    Google Scholar 

  30. Seregard S (1998) Conjunctival melanoma. Surv Ophthalmol 42:321–350

    Article  PubMed  CAS  Google Scholar 

  31. Shields JA, Shields CL, DePotter P (1998) Surgical management of circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg 14:208–215

    Article  CAS  Google Scholar 

  32. Shields CL, Naseripour M, Shields JA, Eagle RC (2001) Topical mitomycin C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology 109: 2129–2133

    Article  Google Scholar 

  33. Shields CL, Demirci H, Shields JA, Spanich C (2002) Dramatic regression of conjunctival and corneal acquired melanosis with topical mitomycin C. Br J Ophthalmol 86:244–245

    Article  PubMed  Google Scholar 

  34. Singh G, Wilson MR, Foster CS (1988) Mitomycin eye drops as treatment for pteyrgium. Ophthalmology 95:813–821

    PubMed  CAS  Google Scholar 

  35. Wilson MW, Hungerford JL, George SM et al (1997) Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol 124:303–311

    PubMed  CAS  Google Scholar 

  36. Wilson MW, Czechonska G, Finger PT et al (2001) Chemotherapy for eye cancer. Surv Ophthalmol 45:416–444

    Article  PubMed  CAS  Google Scholar 

  37. Yu G, Hu D, McCormick SA, Finger PT (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 135:800–806

    Article  PubMed  Google Scholar 

  38. Yuen HKL, Yeung EFY, Nongnart R, Chi SCC, Dennis SC (2002) The use of postoperative topical mitomycin C in the treatment of recurrent conjunctival papilloma. Cornea 21:838–839

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported by The EyeCare Foundation, Inc., and Research to Prevent Blindness, New York City, NY, USA.

Author information

Authors and Affiliations

  1. The New York Eye Cancer Center, The Fifth Floor, 115 East 61st Street, New York, NY, 10021, USA

    Madhavi Kurli & Paul T. Finger

  2. The New York Eye and Ear Infirmary, New York, NY, USA

    Madhavi Kurli & Paul T. Finger

  3. New York University School of Medicine, New York, NY, USA

    Paul T. Finger

Authors
  1. Madhavi Kurli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul T. Finger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul T. Finger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurli, M., Finger, P.T. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefe's Arch Clin Exp Ophthalmo 243, 1108–1114 (2005). https://doi.org/10.1007/s00417-004-1080-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-004-1080-y

Keywords

Search

Navigation